In contrast to the complex role of IFN-γ in the development of MS/EAE, systemic administration of IFN-β has emerged as the most widely used therapy for MS, offering prolonged periods of remission, reduced severity of relapses, and decreased inflammatory lesions in the CNS [40, 41, 42, 43]. The gene discussed is IFNG; the disease is myeloid sarcoma.